Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…Abstract Number: 0480 • ACR Convergence 2020
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…Abstract Number: 0567 • ACR Convergence 2020
Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care
Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…Abstract Number: 0745 • ACR Convergence 2020
Development of Functional Assays to Pre-qualify Human Mesenchymal Stem Cells for Rheumatoid Arthritis Treatment
Background/Purpose: Sero-positive rheumatoid arthritis (RA) is a chronic autoimmune disease that without effective treatment, leads to joint damage and disability. Not all patients respond to…Abstract Number: 0762 • ACR Convergence 2020
Anti-Protein-Arginine Deiminase (PAD) 1 IgG Is a Promising Novel Autoantigen in Rheumatoid Arthritis (RA) and Increases Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Score
Background/Purpose: Over the past years, novel biomarkers have been identified in the sera of rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD)…Abstract Number: 0779 • ACR Convergence 2020
Antibody Responses to Epstein-Barr Virus Are Altered in the Pre-Clinical Period of Rheumatoid Arthritis
Background/Purpose: Viral infections, including infection with Epstein-Barr virus (EBV), have been suggested as environmental risk factors for rheumatoid arthritis (RA). EBV infections are known to…Abstract Number: 0796 • ACR Convergence 2020
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…Abstract Number: 0812 • ACR Convergence 2020
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
Background/Purpose: Biologics have revolutionized the treatment of autoimmune diseases, though costs and payer restrictions have limited who are treated and when these agents are used. …Abstract Number: 0829 • ACR Convergence 2020
International Comparison of Japanese and US Cross Country Utilization of RA Medications
Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…Abstract Number: 0973 • ACR Convergence 2020
Novel Network Tool Highlights Key Features Associated with Disease Pathotypes and Response to Treatment in Early Rheumatoid Arthritis
Background/Purpose: Biomedical research uses many statistical/bioinformatics tools to find genes or proteins differentially expressed between patient group of interest. However, biological elements are related to…Abstract Number: 1010 • ACR Convergence 2020
Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
Background/Purpose: Compared with the general population, patients with RA are at an increased risk of infection and certain malignancies, which may be increased further with…Abstract Number: 1181 • ACR Convergence 2020
Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in rheumatoid arthritis (RA). Ischemic heart disease in RA is often silent and precedes myocardial…Abstract Number: 1197 • ACR Convergence 2020
Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is among the most frequent and severe extra-articular manifestations of RA, contributing significantly to the excess mortality among RA…Abstract Number: 1213 • ACR Convergence 2020
Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis
Background/Purpose: Assessment of disease activity in RA with validated measures, such as the Disease Activity Score with 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)…Abstract Number: 1231 • ACR Convergence 2020
Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years
Background/Purpose: For patients with rheumatoid arthritis (RA), long‑term prevention of structural joint damage is a key treatment goal.1 In the SELECT-EARLY and SELECT-COMPARE trials, upadacitinib…
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 188
- Next Page »